Results 61 to 70 of about 156,559 (321)

An Explainable and Conformal AI Model to Detect Temporomandibular Joint Involvement in Children Suffering from Juvenile Idiopathic Arthritis [PDF]

Proceedings of the IEEE EMBC, 2024, Vol. 1, pp. 1-4, IEEE
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease during childhood and adolescence. The temporomandibular joints (TMJ) are among the most frequently affected joints in patients with JIA, and mandibular growth is especially vulnerable to arthritic changes of the TMJ in children.
arxiv   +1 more source

Rheumatic diseases and multimorbidity

Terapevticheskii arkhiv, 2015
In the past decade, investigators' undeniable and justified interest has not been fading in comorbidities in the presence of rheumatic diseases. The terms "comorbidity" and "multimorbidity" are frequently and not always consciously used as interinterchangeable, confusing the terminology and accordingly the elaboration of strategies for further ...
E.A. Galushko, E.L. Nasonov, A.V. Gordeev   +2 more
openaire   +4 more sources

Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial

Arthritis Care &Research, EarlyView.
Objective This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods In an open‐label, phase 1 study (SELECT‐YOUTH), enrolled patients, aged 2 to <18 years with pcJIA, received body weight–based ...
Hermine I. Brunner, Anna Shmagel, Gerd Horneff, Ivan Foeldvari, Jordi Antón, Athimalaipet V. Ramanan, Yuli Qian, Kristina Unnebrink, Shuai Hao, Heidi S. Camp, Nasser Khan, Wei Liu, Mohamed‐Eslam F. Mohamed   +12 more
wiley   +1 more source

Ontology Based Information Extraction for Disease Intelligence [PDF]

International Journal of Research in Computer Science, 2 (6): pp. 7-19, November 2012. doi:10.7815/ijorcs.26.2012.051, 2012
Disease Intelligence (DI) is based on the acquisition and aggregation of fragmented knowledge of diseases at multiple sources all over the world to provide valuable information to doctors, researchers and information seeking community. Some diseases have their own characteristics changed rapidly at different places of the world and are reported on ...
arxiv   +1 more source

Incidence of and Risk of Mortality After Hip Fractures in Rheumatoid Arthritis Relative to the General Population

Arthritis Care &Research, EarlyView.
Objective Osteoporosis, a known complication of rheumatoid arthritis (RA), increases the risk of hip fracture, which is associated with high morbidity and mortality. Fracture risk estimates in patients with RA treated with contemporary treatment strategies are lacking.
C. Allyson Jones, Pierre Guy, Hui Xie, Eric C. Sayre, Kai Zhao, Diane Lacaille   +5 more
wiley   +1 more source

Influence of biologic and conventional disease-modifying antirheumatic drugs on COVID-19 incidence among rheumatic patients during the first and second wave of the pandemic in Iran

Rheumatology, 2022
Introduction During the SARS-CoV-2 virus pandemic, immunosuppressive agents in treating chronic disease have become a concern, and rheumatic patients are not an exception.
Maryam Sahebari, Zahra Mirfeizi, Zhaleh Shariati-Sarabi, Malihe Dadgar Moghadam, Kamila Hashemzadeh, Mona Firoozabadi   +5 more
doaj   +1 more source

Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual

Arthritis Care &Research, EarlyView.
Objective Organ damage in patients with systemic sclerosis (SSc) in individual organs such as the lungs may be prevented by receiving immunosuppressive drugs (ISs). A new measure of global organ damage, the Scleroderma Clinical Trials Consortium Damage Index (SCTC‐DI), has allowed us to investigate whether receiving ISs may reduce global organ damage ...
Murray Baron, Mandana Nikpour, Dylan Hansen, Susanna Proudman, Wendy Stevens, on behalf of the Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group, Joanne Sahhar, Nava Ferdowsi, Kathleen Morrisroe, Laura Ross, Gene Siew Ngian, Jennifer Walker, Janet Roddy, Lauren Host, Mohammed Osman, Peter Docherty, Paul Fortin, Marvin Jacob Fritzler, Genevieve Gyger, Alena Ikic, Niall Jones, Elzbieta Kaminska, Maggie Larche, Sophie Ligier, Ada Man, Ariel Masetto, Janet Pope, David Robinson, Tatiana Sofia Rodriguez‐Reyna, Mianbo Wang   +29 more
wiley   +1 more source

Long term effectiveness of RA-1 as a monotherapy and in combination with disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis

Journal of Ayurveda and Integrative Medicine, 2018
Background: Data on long term use of Ayurvedic drugs is sparse. They may prove useful if combined with modern medicine in certain clinical situations (integrative medicine).
Arvind Chopra, Manjit Saluja, Toktam Kianifard, Deepa Chitre, Anuradha Venugopalan   +4 more
doaj  

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs

Arthritis Research & Therapy, 2017
Background Treatment with disease-modifying anti-rheumatic drugs (DMARDs) has raised concerns about the risk of malignancies in rheumatoid arthritis (RA) patients.
Soo-Kyung Cho, Jiyoung Lee, Minkyung Han, Sang-Cheol Bae, Yoon-Kyoung Sung   +4 more
doaj   +1 more source

Pharmacogenetics in the rheumatic diseases [PDF]

Annals of the Rheumatic Diseases, 2004
Designing a therapeutic plan that involves the least risk of toxicity and the greatest chance of success is the goal of the modern physician. To better achieve this goal an understanding of the genetic basis for drug efficacy and toxicity is essential.
openaire   +4 more sources